Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This publication discusses the 2021 ESC Guidelines for the prevention of cardiovascular disease in clinical practice and reports no new results.

This study highlights a potential association between semaglutide, a diabetes medication, and increased reports of hair loss, with researchers calling for more rigorous clinical trials to confirm and better understand the risk.

This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.

This study reports that women with polycystic ovary syndrome, especially those with a hyperandrogenic pattern, are at a higher risk for cardiovascular disease compared to other PCOS patients, likely due to related metabolic comorbidities.

This study suggests that sodium-glucose cotransporter-2 inhibitors, alone or with metformin or GLP1RA, may improve metabolic and hormonal parameters in women with polycystic ovary syndrome.

This review discusses various weight loss treatment options for managing PCOS in women, including lifestyle changes, diet, medications, and surgery, but reports no new clinical results.

This review explores how metabolic and psychological factors contribute to binge eating disorder in women with PCOS and highlights the need for non-punitive, comprehensive management strategies.

This review reports that lifestyle modification, including diet and exercise, is essential for managing PCOS, while pharmacological and complementary treatments address specific symptoms like menstrual irregularities and insulin resistance.

This review examines current evidence on personalized management strategies for PCOS, but does not present new clinical results; the authors advocate for treatments tailored to predominant symptoms and individual health profiles.

This abstract does not report specific research results but introduces a book focusing on the intersection of endocrinology and aesthetic medicine and its growing importance in contemporary clinical practice.

This narrative review identifies telogen effluvium as a growing concern linked to weight-loss interventions, such as GLP-1 receptor agonists and bariatric surgery, attributing hair loss to systemic and metabolic stress rather than permanent hair follicle damage.

In this retrospective cohort study, researchers found that exposure to 5-alpha reductase inhibitors and spironolactone in female alopecia patients was not linked to an increased risk of developing malignant or benign gynecologic tumors when compared to minoxidil use.

In this study, analysis of electronic health records suggested that patients taking semaglutide were significantly less likely to experience suicidal ideation compared to those on non-GLP-1 obesity or diabetes medications.

This study observed that methylene blue, a mitochondrial-targeted antioxidant, promotes hair follicle stem cell proliferation and viability through reduced oxidative stress and enhanced β-catenin signaling, and it may also protect against hair loss related to glucagon-like peptide-1 receptor agonists by reducing metabolic stress.

Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.

This review examined the dermatologic side effects and potential treatments benefits of metformin and GLP-1/GIP agonists in managing skin conditions related to hormonal and immune effects in individuals with type 2 diabetes who are overweight or obese.

This study reviews the role of semaglutide in obesity management, emphasizing its substantial weight-loss and metabolic benefits in diverse patients, with a focus on its mechanisms, dosing, efficacy, and safety.

In this retrospective case series, therapeutic responses to immunomodulatory and incretin-based therapies for Dercum's disease showed considerable individual variation, suggesting these treatments might be exploratory options when surgery isn't feasible, though further controlled studies are needed for definitive conclusions.

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

This report details the experiences gained during a pharmacy internship in both hospital and community settings, highlighting the preparation of sildenafil suspensions for hospital use, patient consultations on autoimmune conditions, and educational material creation in community pharmacy, alongside insights into diabetes and ADHD treatments.

This joint position paper by several Polish medical societies examines guidelines and recommendations for managing conditions like obesity, hypertension, and liver disease, underscoring the importance of a collaborative, interdisciplinary approach in treatment. Results are not explicitly reported.

This summary of a pharmacy internship reports on expanding scientific knowledge through diverse activities, including exploring diabetes medications for obesity treatment and discussing the role of nutritional supplements in geriatrics.

This study discusses the rising interest in drug repositioning, particularly in response to COVID-19, and highlights various computational and experimental approaches used for repurposing existing drugs across different diseases, including rare conditions and chronic kidney disease.

This review article discusses the aesthetic impacts of GLP-1 medications like Ozempic (semaglutide), including "Ozempic Face," skin sagging, and loss of lean mass, and explores potential recovery methods such as biostimulators, HIFU, endolaser, and PRP.

In this study, short-term liraglutide treatment led to significant weight loss in obese women with newly diagnosed PCOS and a higher metabolic risk profile compared to metformin.

Tailored medication preparation and ongoing education are crucial for effective treatments.

In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.

In this retrospective study conducted at a dermatology institute in Mexico, researchers analyzed 1,888 adult alopecia cases, identifying alopecia areata as the most common type. The study underscores the importance of regional studies to better understand alopecia patterns and inform management strategies.

This review explores new theories, diagnostic tools, and management strategies for primary cicatricial alopecia but reports no new clinical findings.

This study explores how SARS-CoV-2 interacts with endocrine organs and highlights specific endocrine molecules that help explain the progression and outcomes of COVID-19, especially in patients with certain metabolic conditions.